Keith Flaherty MD

PubMed

• Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.
  Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Claire A Palin, Boryana Petrova
  Cell Reports. Medicine. 2025-07-15
• Facts and Hopes: Toward the Next Quantum Leap in Melanoma.
  Keith T Flaherty, Andrew E Aplin, Michael A Davies, Nir Hacohen, Meenhard Herlyn
  Clinical Cancer Research. 2025-07-15
• Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
  Kelsey R Monson, Robert Ferguson, Joanna E Handzlik, Leah Morales, Jiahan Xiong
  Nature Medicine. 2025-07-01

Journal Articles

• Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor  
  Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
• Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
• A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow Melanoma  
  Keith T Flaherty, Jennifer A Wargo, Wiley
• Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
• When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age  
  Keith Flaherty, MD, Annals of Internal Medicine
• Join now to see all

Lectures

• Tissue Agnostic Drug Development Operational and Scientific Challenges. Tissue Agnostic Drug Development 
  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018